Figure 4 | Scientific Reports

Figure 4

From: Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy

Figure 4

A flowchart of the patients enrolled in the study.

Patients in the OPTIMIZE group (Group I) started LdT 600 mg daily from the baseline and 10 mg of daily ADV was added to patients with suboptimal responses from week 28. Patients in the MONO group (Group II) started LdT monotherapy from the baseline. All of the patients with LdT monotherapy had ADV added once a confirmed virological breakthrough had developed. ITT, intention to treat.

Back to article page